The trial data released by Tandem Diabetes reveal that children with type 1 diabetes who utilized the Control-IQ hybrid closed loop technology saw significant increases in time in range and decreases in A1C from the very first day.
The results of testing an automated insulin administration device in young children with type 1 diabetes were published in The New England Journal of Medicine.
A total of 102 young children, ages 2 to 6, were participated in the trial, and were given the option of receiving either a Control-IQ closed-loop insulin delivery system or the conventional therapy of an insulin pump, numerous daily injections of insulin, and a continuous glucose monitor.
Time in range (TIR), defined as the percentage of time a child’s blood glucose level is between 70 and 180 mg/dL, was the primary outcome measure used to assess the impact of Control IQ technology on children with type 1 diabetes during the course of the trial.
Young children with type 1 diabetes saw their time in range increase from 56.7% at baseline to 69.3% after 13 weeks when using the closed-loop system.
Time in range for those receiving standard care rose from 54.9% to 55.9% during the same time period. TIR varied by 12.4% across the two groups, which translates to around 3 hours each day.
How the technology will contribute to diabetes patients
Researchers are trying to figure out how to better assist young children in controlling their type 1 diabetes. These results imply that hybrid closed-loop insulin delivery devices could be a very successful choice.
This innovation integrates an insulin pump, a continuous glucose monitor, and a computational algorithm that modifies insulin dosing in response to readings from the CGM. Because of this, parents of young children with T1D will feel more at ease knowing that their child is safer from potentially fatal highs and lows in blood sugar.
Over the course of 13 weeks, patients using Control-IQ technology saw significant improvements in their blood glucose control compared to those receiving standard care.
In addition, when compared to the usual care group, children who used the Control-IQ closed loop device technology had lower A1C and mean glucose levels and spent less time in the high glucose range. These results highlight the critical need for persons with type 1 diabetes to begin using cutting-edge diabetes technologies as soon as feasible.
To read our article about “Samsung is creating specialized devices for rivalry with Apple” click here.
